Table 2
Oncologic outcomes according to LPLND status in rectal cancer patients after neoadjuvant chemoradiotherapy

Study	Year	Patients		Local recurrence, %		Free of distant metastasis, %		5-year overall survival, %
		LPLND	No LPLND	LPLND	No LPLND	LPLND	No LPLND	LPLND	No LPLND
Watanabe et al. [25]	2002	53	25	16.9	12	50.9	68
Ishihara et al. [9]	2016	14	34	-	-	-	-	CSS (HR, 0.73; 95% CI, 0.41–1.31)
Georgiou et al. [36]	2017	12	19	50	31.5	88.2	75	60.7	75.2
Nagawa et al. [26]	2001	23	22	4.3	0	69.5	77.2	-	-
Akiyoshi et al. [27]	2014	38	89	2.6	7.8	-	-	83.8‡	74.6‡
Ogura et al. [6]	2019	71	202	5.7*	25.6*	86.5*	69.2*	94.1*,†	79.4*,†
Matsuda et al. [37]	2018	32	13	20	0	74.7	78.6	-	-

LPLND, lateral pelvic lymph node dissection; CSS, cancer-specific survival; HR, hazard ratio; CI, confidence interval; -, not applicable.
*Among patients with pretreatment short-axis diameter of ≥7 mm.
^†Cancer-specific survival.
^‡5-Year relapse-free survival.